Restoring the Architecture: A Rapid Clinical Perspective on Bone-Mineral Density and Osteoporosis
Open Access
- 11 May 2017
- journal article
- Published by AOSIS in South African Family Practice
- Vol. 59 (2) , 22-31
Abstract
Osteoporosis is a highly prevalent and debilitating condition that contributes to the risk of fracture in both women and men. The current paper will provide a rapid clinical overview of the condition and the current pharmacotherapeutic approaches applied in its treatment. We close with a summary of novel treatment strategies currently being developed and explain the role of sequential combination therapy in the management of established osteoporosis.Keywords
This publication has 77 references indexed in Scilit:
- Greater Gains in Spine and Hip Strength for Romosozumab Compared With Teriparatide in Postmenopausal Women With Low Bone MassJournal of Bone and Mineral Research, 2017
- Effects of Abaloparatide-SC on Fractures and Bone Mineral Density in Subgroups of Postmenopausal Women With Osteoporosis and Varying Baseline Risk FactorsJournal of Bone and Mineral Research, 2016
- Effects of Daily or Cyclic Teriparatide on Bone Formation in the Iliac Crest in Women on No Prior Therapy and in Women on AlendronateJournal of Bone and Mineral Research, 2016
- Diagnosis and Management of Osteonecrosis of the Jaw: A Systematic Review and International ConsensusJournal of Bone and Mineral Research, 2014
- The Effects of Calcium Supplementation on Verified Coronary Heart Disease Hospitalization and Death in Postmenopausal Women: A Collaborative Meta-Analysis of Randomized Controlled TrialsJournal of Bone and Mineral Research, 2014
- Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosisOsteoporosis International, 2009
- Health Risks and Benefits 3 Years After Stopping Randomized Treatment With Estrogen and ProgestinJAMA, 2008
- FRAX™ and the assessment of fracture probability in men and women from the UKOsteoporosis International, 2008
- Reduction of Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis Treated With RaloxifeneResults From a 3-Year Randomized Clinical TrialJAMA, 1999
- Function of osteocytes in boneJournal of Cellular Biochemistry, 1994